Aripiprazole

This page contains recent news articles, when available, and an overview of Aripiprazole but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Aripiprazole
(when available)

Pharmacology and use:
Aripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. For the treatment of schizophrenia

Mechanism Of Action:
Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5- HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors and moderate affinity for the serotonin reuptake pump. Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors. Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptor.

News Articles on Aripiprazole

Many antipsychotic users not getting needed tests  -  04 Jan 2010
These so-called "second-generation" antipsychotic drugs, which include olanzapine (Zyprexa), risperidone (Risperdal) and aripiprazole (Abilify), ... Reuters

Metabolic risks remain largely unmonitored in Medicaid patients taking ...  -  04 Jan 2010
Prescriptions of the lower-risk drug aripiprazole increased, but this may also be attributable to the elimination of prior authorization for the drug in ... EurekAlert (press release)

Treatment of psychotic symptoms in bipolar disorder with aripiprazole ...  -  ‎Dec 31, 2009‎
We present a systematic review and meta-analysis of the available clinical trials concerning the usefulness of aripiprazole in the treatment of the ... 7thSpace Interactive (press release)

Atypical Antipsychotics Increase Cardiometabolic Risk in Children  -  ‎Dec 29, 2009‎
There were no metabolic abnormalities or significant changes from baseline with aripiprazole treatment. This study was published in October, ... Psychiatric Times

Pharmacotherapy for borderline personality disorder: Cochrane systematic ...  -  ‎Dec 31, 2009‎
Among second-generation antipsychotics (SGAs), aripiprazole was found to have both significant effects in the reduction of the core pathological symptoms of ... British Journal of Psychiatry

Antipsychotic Use and Risk for Hyperglycemia in Elderly Patients With DM  -  ‎Dec 14, 2009‎
An analysis of a large adverse events database on diabetes-related adverse events within the group of atypical APDs—aripiprazole, clozapine, olanzapine, ... Archives of Internal Medicine

Antipsychotic Prescribing in Children: What We Know—What We Need to Know  -  ‎Dec 16, 2009‎
The average weight increase ranged from 18.7 pounds (olanzapine) to 9.7 pounds (aripiprazole). 3 In the second report, Medicaid-insured youth were found to ... Psychiatric Times

Psychiatry: Science or Science Fiction?  -  ‎Dec 23, 2009‎
..."The addition of aripiprazole to risperidone or quetiapine was not associated with improvement in psychiatric symptoms but was generally safe and well ... Gather.com

2000 patent applications by MNCs withdrawn, rejected: PPMA  -  ‎Dec 24, 2009‎
Gabapentin, combination of Pregablin and Gabapentin, Azithromycin, Aripiprazole, Benzimidazole, Tegaserode, atorvastatin, Resuvastatin and Clopidogrel. ... Daily Times

Aripiprazole Generally Safe, Tolerable for Children With Autism-Related ...  -  ‎Nov 12, 2009‎
The findings in the original placebo-controlled trials showed that aripiprazole was superior to placebo in reducing irritable and aggressive symptoms in ... DG News

Use Of Antipsychotic Medications By Children And Adolescents Associated With ...  -  ‎Oct 28, 2009‎
Patients were treated with the antipsychotic medications aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks. After a median (midpoint) of ... Science Daily (press release)

Generic Name: Aripiprazole, Arizol, Arlemide, Brisking, Ilimit, Irazem, Real One  -  ‎Nov 11, 2009‎
Abilify (generic name: Aripiprazole; brand names include: Arizol / Arlemide / Brisking / Ilimit / Irazem) is an atypical antipsychotic. ... Pattaya Daily News

Kids using anti-psychotic drugs gained weight: study  -  ‎Oct 28, 2009‎
...well as mood disorders, are often prescribed second-generation antipsychotic medications such as aripiprazole, olanzapine, quetiapine, and risperidone. ... AFP

Can Balloon Boy finally shoot down our obsession with fame?  -  ‎Oct 20, 2009‎
...ultimately, the kind of entertainment suitable only to a mental patient crammed full of Aripiprazole 9 or any other third-generation anti-psychotic. ... Globe and Mail

Children Gain Weight on Antipsychotic Medications  -  ‎Oct 31, 2009‎
Average gain was as follows: 18.7 pounds with onanzapine, 13.7 pounds with quetiapine, 11.7 pounds with risperidone, and 9.7 pounds with aripiprazole. ... Healia Health (blog)

B-MS posts strong sales for most of its drugs  -  ‎Oct 23, 2009‎
Biopharmaceutical turnover was up 6% to $4.80 billion, driven by Plavix (clopidogrel), up 8% to $1.55 billion, while sales of Abilify (aripiprazole) climbed ... Pharma Times

Bipolar drug market “to plummet from 2011â€?  -  ‎Nov 10, 2009‎
Bristol-Myers Squibb/Otsuka's Abilify (aripiprazole) and Pfizer's Geodon (ziprasidone), according to the study, from Decision Resources. ... Pharma Times

BristolMyers Squibb Company Reports Operating Results (10-Q)  -  ‎Oct 22, 2009‎
PLAVIX* (clopidogrel bisulfate) and ABILIFY* (aripiprazole) continue to drive sales growth with sales increases of 8% and 16% for the three months ended ... GuruFocus.com

This Week in JAMA  -  ‎Oct 27, 2009‎
Correll and colleagues (SEE ARTICLE) assessed the association of 12-week treatment with aripiprazole, olanzapine, quetiapine, or risperidone with body ... Journal of American Medical Association (subscription)

Antipsychotic Drugs Can Cause Rapid Weight Gain in Kids  -  ‎Nov 3, 2009‎
Zyprexa or olanzapine made by Eli Lilly, Abilify or aripiprazole made by Bristol-Myers Squibb, and Seroquel or quetiapine made by AstraZeneca. ... Fars News Agency

Antipsychotic Drugs Put Kids at Risk  -  ‎Nov 1, 2009‎
...patients on average had gained 18.7 pounds with olanzapine, 13.4 pounds with quetiapine, 11.7 pounds with risperidone and 9.7 pounds with aripiprazole. ... Ivanhoe

Anti-Psychotic Medications Associated With Childhood Weight Gain  -  ‎Oct 28, 2009‎
Specifically, an average of 18.7 pounds with olanzapine, by 13.4 pounds with quetiapine, by 11.7 pounds with risperidone and by 9.7 lbs. with aripiprazole, ... Gant Daily

On the Pulse - 6th November 2009  -  ‎Nov 6, 2009‎
...all four drugs studied were associated with significant weight gains, from a mean of 4.4 kg with aripiprazole to 8.8 kg with olanzapine. ... OnMedica

New systematic study for managing treatment-resistant bipolar depression  -  ‎Oct 27, 2009‎
...carbamazepine 800 mg, aripiprazole 30 mg, olanzapine 5 mg (intolerant), ziprasidone 160 mg (intolerant), fluoxetine 80 mg, duloxetine 90 mg, ... News-Medical.net

New Report Just Published Blood-Brain Barrier: Bridging Options for Drug ...  -  ‎Oct 23, 2009‎
...for treatment of depression) and Bristol-Myers Squibb's/Otsuka's Abilify (aripiprazole, for treatment of bipolar disorder and schizophrenia). ... Live-PR.com (Pressemitteilung)

Les anti-psychotiques pour enfants créent des problèmes de poids  -  ‎Oct 28, 2009‎
Et il n'y avait pas de changements importants observés pour l'aripiprazole ou dans les groupes témoins non traités, selon les chercheurs. ... Le blog bébé (Blog)

Les antipsychotiques causent un rapide et important gain de poids chez les jeunes  -  ‎Oct 27, 2009‎
...pour la première fois, un des quatre antipsychotiques Abilify (aripiprazole), Risperdal (risperidone), Seroquel (quetiapine) ou Zyprexa (olanzapine). ... PsychoMédia

Des antipsychotiques provoquent l'obésité chez les enfants et les adolescents  -  ‎Nov 2, 2009‎
Ils se sont tous vus prescrire quatre différents types d'antipsychotiques à savoir l'aripiprazole, l'olanzapine, le quetiapine et le risperidone pendant 12 ... Algérie Soir

Brand Names/Synonyms:
Aripiprazole is also known by the following brand names and/or synonymsAbilify; Abilitat; Aripiprazole; Aripiprazole [Usan]; OPC 31

Drug Category:
Aripiprazole is categorized under the following by the FDA: Antipsychotics; ATC:N05AX12

Dosage Forms:
Not Available

Absorption:
Not Available

Interactions:
[an error occurred while processing this directive]



Chemical IUPAC Name:
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy